Balaji Amines Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8cuq5vu6zxjodt3rt399ycrt.pdf

Key Takeaways


DMF: The China Equation Flipped

Ram Reddy: "We have waited almost 6 to 9 months to understand whether the China will take U-turn or how long they will do like this or whether they will again re-enter with the new prices here. But we could see that this is not a temporary. The people understood realistic price is this and maybe some of the plants because of the gas prices all over world including China have come to a realistic level."

Subsidiary: Diversification De-risks the Story


New Capacity: DMC, Propylene Glycol & the Phase-2 Pipeline

Ram Reddy: "We have it totally different technology and we will have the price advantage definitely. We don't see that the current competition and all those things, we will be definitely comfortable with our price once we start this new technology."

Product-Mix Resilience & Margin Mechanics

Ram Reddy: "Actually, I can say the good numbers and the bad period. What we can say, this has only happened when you have the multiple products of basket. One product is not doing well then another product in helping you, that is a specialty with the Balaji Amines where we have number of products and number of applications of the products."

EDA: European Force Majeure Windfall


FY23 Guidance: Conservative by Design

Ram Reddy: "Looking into the peak prices, we have tried that if the prices come down even though the bottom line may not impact. But the revenues may impact and adding the new products will add. All put together I have taken this conservative number of Rs. 2,500 crores."

Guidance & Commitments

CommitmentSpecificsTimeline
DMC/propylene glycol plant startOperations commence; sales from Q1 FY23End of June 2022
DMF capacity utilizationRamp to 70–80% from ~42% in FY22FY23
Subsidiary capacity utilization70–80% (up from ~56% in FY22)FY23
Subsidiary turnover₹700–750 cr, factoring 5–7% price correctionFY23
Consolidated revenue₹2,500 cr (conservative, per management)FY23
Consolidated EBITDA marginMinimum 24–26% sustainableFY23 and ongoing
Volume growthMinimum 10–15% over FY22’s 1,15,000 MTFY23
Export shareAt least 30–35% of total revenueGoing forward
Phase-2 CAPEX₹300–400 cr spend beginsFY23–FY24
Phase-2 productionPlants commence productionMid-FY24 to end-FY25
Acetonitrile plantOperational with new cost-advantage technologyMid-FY24
Second DMF plant (30,000 tons)Capacity addition; ~50% India market shareFY25–26 window
Subsidiary debottlenecking10–15% capacity growth on existing baseUnder evaluation

Key Metrics

MetricQ4 FY22
Revenue₹781 crores, up 87% YoY vs ₹418 crores in Q4 FY21
Total volume33,780 MT, up 18.3% YoY vs 28,547 MT in Q4 FY21
EBITDA₹199 crores, up 50% YoY vs ₹133 crores in Q4 FY21
EBITDA margin25.50%, vs 31.7% in Q4 FY21
PAT₹131 crores, up 47% YoY vs ₹89 crores in Q4 FY21
PAT margin16.8%, vs 21.3% in Q4 FY21
Diluted EPS₹33.56 per equity share, vs ₹26.08 in Q4 FY21
FY23 consolidated revenue guidance₹2,500 crores, conservative estimate factoring potential price corrections
FY23 consolidated EBITDA margin guidance24% to 26% minimum, sustainable range
Subsidiary Q4 sales volume4,903 MT, vs 3,669 MT in Q4 FY21 and 3,887 MT in Q3 FY22
Subsidiary FY22 capacity utilizationabout 56%
Subsidiary FY23 revenue guidance₹700 to 750 crores, at 70% to 80% capacity utilization
DMF plant Q4 capacity utilizationaround 65%
DMF plant FY23 expected capacity utilization70% to 80%, up from about 42% in FY22
DMC facility FY23 expected capacity utilizationabout 60%, first year of operations
Phase-2 Greenfield CAPEX for FY23 and FY24₹300 to 400 crores, majority from internal accruals